BCPEM
EPZM

Bain Capital Public Equity Management’s Epizyme, Inc EPZM Stock Holding History

Bain Capital Public Equity Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-180,574
Closed -$3.44M – 108
2017
Q3 		$3.44M Sell
180,574
-106,276
-37% -$1.62M 0.22% 48
2017
Q2 		$4.33M Buy
+286,850
New +$4.34M 0.26% 44

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Bain Capital Public Equity Management's EPZM Position: Q4 2017 in Review

Bain Capital Public Equity Management sold out of Epizyme, Inc (EPZM) in Q4 2017, closing a stake of 180,574 shares — an estimated $3.44M sold.

Bain Capital Public Equity Management first reported a position in EPZM in Q2 2017 and held it in 2 quarters. The position peaked at $4.33M in Q2 2017. 101 funds tracked by Wall St. Rank hold EPZM as of Q4 2017.

  • Bain Capital Public Equity Management reported no remaining Epizyme, Inc position as of Q4 2017 after selling out during the quarter.
  • Bain Capital Public Equity Management sold 180,574 Epizyme, Inc shares in Q4 2017, an estimated $3.44M.
  • Bain Capital Public Equity Management first reported a position in Epizyme, Inc in Q2 2017 and held it in 2 quarters.
  • Bain Capital Public Equity Management's Epizyme, Inc position peaked at $4.33M in Q2 2017.
  • 101 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2017.

Based on Bain Capital Public Equity Management's 13F filing for Q4 2017, filed 14 Feb 2018.